» Articles » PMID: 26388395

Mitochondrial Dysfunction Associated with Glucocerebrosidase Deficiency

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2015 Sep 22
PMID 26388395
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

The lysosomal hydrolase glucocerebrosidase (GCase) is encoded for by the GBA gene. Homozygous GBA mutations cause Gaucher disease (GD), a lysosomal storage disorder. Furthermore, homozygous and heterozygous GBA mutations are numerically the greatest genetic risk factor for developing Parkinson's disease (PD), the second most common neurodegenerative disorder. The loss of GCase activity results in impairment of the autophagy-lysosome pathway (ALP), which is required for the degradation of macromolecules and damaged organelles. Aberrant protein handling of α-synuclein by the ALP occurs in both GD and PD. α-synuclein is the principle component of Lewy bodies, a defining hallmark of PD. Mitochondrial dysfunction is also observed in both GD and PD. In this review we will describe how mitochondria are affected following loss of GCase activity. The pathogenic mechanisms leading to mitochondria dysfunction will also be discussed, focusing on the likely inhibition of the degradation of mitochondria by the ALP, also termed mitophagy. Other pathogenic cellular processes associated with GBA mutations that might contribute, such as the unfolding of GCase in the endoplasmic reticulum, calcium dysregulation and neuroinflammation will also be described. Impairment of the ALP and mitochondria dysfunction are common pathogenic themes between GD and PD and probably explain why GBA mutations increase the risk of developing PD that is very similar to sporadic forms of the disease.

Citing Articles

Targeting the Interplay Between Autophagy and the Nrf2 Pathway in Parkinson's Disease with Potential Therapeutic Implications.

Liu M, Liu S, Lin Z, Chen X, Jiao Q, Du X Biomolecules. 2025; 15(1).

PMID: 39858542 PMC: 11764135. DOI: 10.3390/biom15010149.


Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease.

Gu S, Xie Z, Gu M, Wang C, Xu L, Gao C Sci Rep. 2024; 14(1):15107.

PMID: 38956066 PMC: 11219851. DOI: 10.1038/s41598-024-62910-6.


Whole-exome sequencing reveals genetic variants that may play a role in neurocytomas.

Khowal S, Zhang D, Yong W, Heaney A J Neurooncol. 2024; 166(3):471-483.

PMID: 38319496 DOI: 10.1007/s11060-024-04567-9.


Meta-analysis of the association of prosaposin polymorphisms rs4747203 and rs885828 with risk of Parkinson's disease.

Zhu L, Zhang X, Guan Y, Zhu Y, Zhou Q, Liu B Acta Neurol Belg. 2024; 124(2):573-580.

PMID: 38206457 DOI: 10.1007/s13760-023-02446-0.


N-acetylcysteine Pharmacology and Applications in Rare Diseases-Repurposing an Old Antioxidant.

Sahasrabudhe S, Terluk M, Kartha R Antioxidants (Basel). 2023; 12(7).

PMID: 37507857 PMC: 10376274. DOI: 10.3390/antiox12071316.


References
1.
Matalonga L, Arias A, Coll M, Garcia-Villoria J, Gort L, Ribes A . Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. J Inherit Metab Dis. 2013; 37(3):439-46. DOI: 10.1007/s10545-013-9668-1. View

2.
Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, AGHAI E . Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996; 89(9):691-4. DOI: 10.1093/qjmed/89.9.691. View

3.
Geisler S, Holmstrom K, Skujat D, Fiesel F, Rothfuss O, Kahle P . PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010; 12(2):119-31. DOI: 10.1038/ncb2012. View

4.
Cleeter M, Cooper J, Darley-Usmar V, Moncada S, Schapira A . Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 1994; 345(1):50-4. DOI: 10.1016/0014-5793(94)00424-2. View

5.
Grace M, Ashton-Prolla P, Pastores G, Soni A, Desnick R . Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease. J Clin Invest. 1999; 103(6):817-23. PMC: 408142. DOI: 10.1172/JCI5168. View